Next Article in Journal
BrWRKY65, a WRKY Transcription Factor, Is Involved in Regulating Three Leaf Senescence-Associated Genes in Chinese Flowering Cabbage
Next Article in Special Issue
Deconstructing Signaling Pathways in Cancer for Optimizing Cancer Combination Therapies
Previous Article in Journal
Activation of Magnesium Lignosulfonate and Kraft Lignin: Influence on the Properties of Phenolic Resin-Based Composites for Potential Applications in Abrasive Materials
Previous Article in Special Issue
Down’s Syndrome and Triple Negative Breast Cancer: A Rare Occurrence of Distinctive Clinical Relationship
Open AccessReview

Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy

1
Comprehensive Breast Health Center, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan
2
Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei 112, Taiwan
3
Institute of Biopharmaceutical Sciences, National Yang-Ming University, No. 155, Sec. 2, Li-Nong Street, Taipei 112, Taiwan
4
Faculty of Pharmacy, National Yang-Ming University, No. 155, Sec. 2, Li-Nong Street, Taipei 112, Taiwan
5
School of Medicine, National Yang-Ming University, No. 155, Sec. 2, Li-Nong Street, Taipei 112, Taiwan
6
Department of Medical Research, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan
7
National Center of Excellence for Clinical Trial and Research, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei 100, Taiwan
*
Authors to whom correspondence should be addressed.
Academic Editor: Terrence Piva
Int. J. Mol. Sci. 2017, 18(6), 1234; https://doi.org/10.3390/ijms18061234
Received: 2 May 2017 / Revised: 1 June 2017 / Accepted: 5 June 2017 / Published: 8 June 2017
(This article belongs to the Special Issue Alterations to Signalling Pathways in Cancer Cells)
The Src homology 2 (SH2) domain-containing protein tyrosine phosphatase 1 (SHP-1), a non-receptor protein tyrosine phosphatase, has been reported as a negative regulator of phosphorylated signal transducer and activator of transcription 3 (STAT3) and linked to tumor development. In this present review, we will discuss the importance and function of SHP-1/p-STAT3 signaling in nonmalignant conditions as well as malignancies, its cross-talk with other pathways, the current clinical development and the potential role of inhibitors of this pathway in anticancer therapy and clinical relevance of SHP-1/p-STAT3 in cancers. Lastly, we will summarize and highlight work involving novel drugs/compounds targeting SHP-1/p-STAT3 signaling and combined strategies that were/are discovered in our and our colleagues’ laboratories. View Full-Text
Keywords: SHP-1 (SH2 domain-containing protein tyrosine phosphatase-1); STAT3 (signal transducer and activator of transcription 3); cancer therapy SHP-1 (SH2 domain-containing protein tyrosine phosphatase-1); STAT3 (signal transducer and activator of transcription 3); cancer therapy
Show Figures

Graphical abstract

MDPI and ACS Style

Huang, T.-T.; Su, J.-C.; Liu, C.-Y.; Shiau, C.-W.; Chen, K.-F. Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy. Int. J. Mol. Sci. 2017, 18, 1234.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop